Fenoglide

Hypertriglyceridemia, Hypertriglyceridemia, Primary Hypercholesterolemia + 2 more
Treatment
8 FDA approvals
15 Active Studies for Fenoglide

What is Fenoglide

FenofibrateThe Generic name of this drug
Treatment SummaryFenofibrate is a medication used to lower cholesterol and triglycerides in people with primary hypercholesterolemia, mixed dyslipidemia, and severe hypertriglyceridemia. It was approved by the FDA in 1993 and is similar to other medications such as clofibrate and gemfibrozil.
Tricoris the brand name
image of different drug pills on a surface
Fenoglide Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Tricor
Fenofibrate
2002
421

Approved as Treatment by the FDA

Fenofibrate, also known as Tricor, is approved by the FDA for 8 uses which include Severe Hypertriglyceridemia (sHTG) and Hypertriglyceridemia .
Severe Hypertriglyceridemia (sHTG)
Hypertriglyceridemia
Hypertriglyceridemia
Hypertriglyceridemia
Primary Hypercholesterolemia
severe Fredrickson Type V Hypertriglyceridemia
severe Fredrickson Type IV Hypertriglyceridemia
Dyslipidemias

Effectiveness

How Fenoglide Affects PatientsFenofibrate is a type of medication that helps your body manage cholesterol and triglyceride levels. It is usually taken once a day, and its effects last for 19-27 hours. A proper dose of fenofibrate is typically between 50-150mg per day. Patients should be aware of the potential risks of taking this drug, such as rhabdomyolysis, myopathy and cholelithiasis.
How Fenoglide works in the bodyFenofibrate increases the body's ability to break down fats. It does this by activating a protein called PPARα. When this protein is turned on, more molecules are produced that help break down fat. This process can be hard on the liver, and in rare cases can cause cirrhosis or chronic active hepatitis.

When to interrupt dosage

The suggested measure of Fenoglide is influenced by the diagnosed state, for example, grave Fredrickson Type V Hypertriglyceridemia, Dyslipidemias and Hypertriglyceridemia. The magnitude of dosage shifts according to the approach of delivery (e.g. Oral or Tablet, film coated) provided in the subsequent table.
Condition
Dosage
Administration
Hypertriglyceridemia
145.0 mg, 48.0 mg, , 160.0 mg, 54.0 mg, 43.0 mg, 130.0 mg, 67.0 mg, 200.0 mg, 134.0 mg, 1.45 mg, 1.6 mg, 40.0 mg, 120.0 mg, 150.0 mg, 50.0 mg, 100.0 mg, 30.0 mg, 90.0 mg, 87.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral
Hypertriglyceridemia
145.0 mg, 48.0 mg, , 160.0 mg, 54.0 mg, 43.0 mg, 130.0 mg, 67.0 mg, 200.0 mg, 134.0 mg, 1.45 mg, 1.6 mg, 40.0 mg, 120.0 mg, 150.0 mg, 50.0 mg, 100.0 mg, 30.0 mg, 90.0 mg, 87.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral
Primary Hypercholesterolemia
145.0 mg, 48.0 mg, , 160.0 mg, 54.0 mg, 43.0 mg, 130.0 mg, 67.0 mg, 200.0 mg, 134.0 mg, 1.45 mg, 1.6 mg, 40.0 mg, 120.0 mg, 150.0 mg, 50.0 mg, 100.0 mg, 30.0 mg, 90.0 mg, 87.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral
Dyslipidemias
145.0 mg, 48.0 mg, , 160.0 mg, 54.0 mg, 43.0 mg, 130.0 mg, 67.0 mg, 200.0 mg, 134.0 mg, 1.45 mg, 1.6 mg, 40.0 mg, 120.0 mg, 150.0 mg, 50.0 mg, 100.0 mg, 30.0 mg, 90.0 mg, 87.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral
Hypertriglyceridemia
145.0 mg, 48.0 mg, , 160.0 mg, 54.0 mg, 43.0 mg, 130.0 mg, 67.0 mg, 200.0 mg, 134.0 mg, 1.45 mg, 1.6 mg, 40.0 mg, 120.0 mg, 150.0 mg, 50.0 mg, 100.0 mg, 30.0 mg, 90.0 mg, 87.0 mg
Oral, Tablet, , Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Capsule, Capsule - Oral, Tablet, coated, Tablet, coated - Oral

Warnings

Fenoglide has three contraindications, so it should not be consumed while suffering from the ailments detailed in the following table.Fenoglide Contraindications
Condition
Risk Level
Notes
Liver Diseases
Do Not Combine
Gallbladder Diseases
Do Not Combine
Severe Hypersensitivity Reactions
Do Not Combine
Fenofibrate may interact with Pulse Frequency
There are 20 known major drug interactions with Fenoglide.
Common Fenoglide Drug Interactions
Drug Name
Risk Level
Description
Acenocoumarol
Major
The metabolism of Acenocoumarol can be decreased when combined with Fenofibrate.
Aluminium clofibrate
Major
The risk or severity of adverse effects can be increased when Fenofibrate is combined with Aluminium clofibrate.
Axitinib
Major
The metabolism of Axitinib can be decreased when combined with Fenofibrate.
Bezafibrate
Major
The risk or severity of adverse effects can be increased when Fenofibrate is combined with Bezafibrate.
Brigatinib
Major
The metabolism of Brigatinib can be decreased when combined with Fenofibrate.
Fenoglide Toxicity & Overdose RiskThe lowest toxic dose of fenofibrate in rats is greater than 2g/kg and 1600mg/kg in mice. To treat an overdose, supportive care such as monitoring vital signs and observing the patient's condition is recommended. Vomiting or stomach pumping may be used to remove the drug from the body, however dialysis is not expected to be useful since fenofibrate binds to proteins.
image of a doctor in a lab doing drug, clinical research

Fenoglide Novel Uses: Which Conditions Have a Clinical Trial Featuring Fenoglide?

At present, 15 active trials are investigating the potential of Fenoglide to mitigate severe Fredrickson Type V Hypertriglyceridemia, Hypertriglyceridemia and Dyslipidemias.
Condition
Clinical Trials
Trial Phases
Primary Hypercholesterolemia
8 Actively Recruiting
Phase 3, Phase 2, Not Applicable
Hypertriglyceridemia
5 Actively Recruiting
Phase 3
Hypertriglyceridemia
0 Actively Recruiting
Hypertriglyceridemia
0 Actively Recruiting
Dyslipidemias
1 Actively Recruiting
Phase 2

Fenoglide Reviews: What are patients saying about Fenoglide?

5Patient Review
12/5/2008
Fenoglide for High Amount of Triglyceride in the Blood
5Patient Review
3/15/2010
Fenoglide for High Amount of Triglyceride in the Blood
5Patient Review
9/15/2010
Fenoglide for Combined High Blood Cholesterol and Triglyceride Level
5Patient Review
10/25/2010
Fenoglide for Combined High Blood Cholesterol and Triglyceride Level
5Patient Review
4/20/2016
Fenoglide for High Amount of Triglyceride in the Blood
I'm taking the tablet form of this medication, but I would prefer capsules.
5Patient Review
1/30/2011
Fenoglide for High Amount of Triglyceride in the Blood
I unfortunately had to stop taking this medication after only two days due to incredibly severe nausea and upset stomach. I also have acid reflux, so it's possible that the two medications didn't mix well.
5Patient Review
1/30/2012
Fenoglide for High Cholesterol
This treatment lowered my triglyceride levels by more than 50% and improved my high density cholesterol by 20%.
3.7Patient Review
1/11/2010
Fenoglide for Combined High Blood Cholesterol and Triglyceride Level
3.7Patient Review
8/18/2017
Fenoglide for Combined High Blood Cholesterol and Triglyceride Level
When I started this treatment, my triglyceride level was 477. Six months later, it had decreased to 176. I'm really amazed by the results.
3Patient Review
10/3/2012
Fenoglide for High Cholesterol
I've been taking this medication for a little while now and have definitely seen an improvement in my triglyceride levels.
2.3Patient Review
1/13/2014
Fenoglide for High Amount of Triglyceride in the Blood
My health has declined since taking this treatment.
2.3Patient Review
12/3/2013
Fenoglide for Combined High Blood Cholesterol and Triglyceride Level
This drug has been a lifesaver! My triglycerides were 1160 four months ago, and now they're down to 120. My cholesterol was 474 and is now 157. When combined with diet and exercise, this medication really helped lower my numbers.
1Patient Review
10/8/2009
Fenoglide for High Amount of Triglyceride in the Blood

Patient Q&A Section about fenoglide

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How does fenofibrate work?

"Fenofibrate is used to lower bad cholesterol and fats by increasing the natural substance that breaks down fats."

Answered by AI

What is the brand name for fenofibrate?

"Fenofibrate is a drug used to treat high cholesterol levels. It comes in the form of an oral tablet or oral capsule. The brand names for fenofibrate are Fenoglide, Tricor, and Triglide."

Answered by AI

What are the side effects of fenofibrate 145 mg?

"Liver function may increase with this medication, as well as respiratory and abdominal pain. There is also the potential for back pain, increased CPK, headaches, constipation, and nausea."

Answered by AI

What is fenoglide used for?

"Fenoglide (fenofibrate) is a drug that helps regulate lipids like cholesterol and triglycerides in the blood. It is used to treat high levels of cholesterol and triglycerides."

Answered by AI

Clinical Trials for Fenoglide

Image of Clinical Research Site 4 in Santa Clarita, United States.

Plozasiran for Hypertriglyceridemia

18+
All Sexes
Santa Clarita, CA
This study will evaluate the efficacy and safety of plozasiran in approximately 288 adult participants with severe hypertriglyceridemia (SHTG) and history of at least two prior acute pancreatitis (AP) events not attributed to other etiologies, with at least one occurring within the last 12 months prior to screening. Eligible participants will be randomly assigned in a double-blind manner to either receive plozasiran 25 mg by subcutaneous (SC) injection every three months (Q3M) or matching placebo. Enrolled participants will be counseled to remain on the specified low-fat diet and background medications throughout the study. Following completion of the double-blind treatment period, or if the participant has a positively adjudicated AP event (whichever occurs first), participants will transition to the 12-month Open-Label Extension (OLE) treatment period receiving plozasiran 25 mg by SC injection Q3M.
Phase 3
Recruiting
Clinical Research Site 4 (+9 Sites)Arrowhead Pharmaceuticals
Image of Atlantic Medical Group in Clark, United States.

Supportive Care for High Cholesterol

18 - 120
All Sexes
Clark, NJ
Hypercholesterolemia is recognized as the major driver for cardiovascular morbidity and mortality. To help address this in our community, Atlantic Medical Group (AMG) formed a lipid workgroup chaired by Robert D. Fishberg, MD, and Jeffrey N. Feldman, MD. The overarching goal of the lipid workgroup is to enhance the treatment of lipid disorders in those patients with abnormal lipid levels by improving access to resources at the primary care practice level and specialty level. We aim to develop a model for primary and secondary prevention that integrates guidelines for treatment at the practice level. Our primary objective is to identify high-risk patients by utilizing the electronic health record and partnering with patients' primary care providers to provide comprehensive medical management.
Recruiting
Has No Placebo
Atlantic Medical Group (+1 Sites)Robert D Fishberg, MDRegeneron Pharmaceuticals
Have you considered Fenoglide clinical trials? We made a collection of clinical trials featuring Fenoglide, we think they might fit your search criteria.Go to Trials
Image of University of Pennsylvania, Perelman School of Medicine in Philadelphia, United States.

Cascade Screening for High Cholesterol

18+
All Sexes
Philadelphia, PA
The goal of this clinical trial is to test two implementation strategies (automated health system \[Penn Medicine\]-mediated strategy vs. Family Heart Foundation-mediated strategy using a patient navigator) versus usual care to promote family cascade screening for familial hypercholesterolemia (FH) in Penn Medicine patients diagnosed with FH ("probands"). The main questions this study aims to answer are: (1) evaluating the effect of the three approaches on reach (proportion of probands who have at least one family member who completes screening), number of family members screened, number of family members diagnosed with FH, and proband LDL-C levels; and (2) identifying implementation strategy mechanisms focusing on health equity using mixed methods and oversampling populations that experience disparities. Participants (probands) in the active arms (health system \[Penn Medicine\]-mediated, Family Heart Foundation-mediated) will receive messaging that provides education about FH and provides instructions for participating in family cascade screening. A subset of probands will be invited to complete a qualitative interview about their experience receiving the implementation strategy. The research team will compare the active arms to Penn Medicine usual care for cascade screening to evaluate whether the active arms are more effective at promoting cascade screening than usual care.
Waitlist Available
Has No Placebo
University of Pennsylvania, Perelman School of Medicine
Have you considered Fenoglide clinical trials? We made a collection of clinical trials featuring Fenoglide, we think they might fit your search criteria.Go to Trials
Image of University of Maryland Amish Research Clinic in Lancaster, United States.

Direct Contact Genetic Screening for High Cholesterol

18+
All Sexes
Lancaster, PA
An important aspect of successful genomic medicine implementation is developing effective approaches for screening at-risk family members after probands are identified, also known as cascade screening. Most cascade screening studies conducted to date have been conducted outside the US, and very few studies have used a rigorous approach involving a comparator group or randomized controlled design. A major question in the field is how to most effectively implement cascade screening, given commonly cited communication barriers, while respecting privacy among probands and family members. This study will conduct a randomized controlled trial to assess direct contact of relatives by study team members vs indirect, or proband-initiated, contact. We will assess efficacy of the cascade screening intervention, patient-centered outcomes regarding mental, physical, and psychosocial outcomes in probands and family members, and implementation evaluation outcomes. Individuals who are known to carry the KCNQ1 Met224Thr or APOB Arg3527Gln variant will be eligible to participate. After providing consent and being deemed eligible, individuals will be randomized in a 1:1 manner into the direct or indirect contact of family members arm of the study. The randomization will be stratified by variant to ensure equal representation of each variant in the study arms. Individuals in the indirect arm will be instructed to contact their first-degree family members about the opportunity to be screened. They will be provided with a disease-specific pamphlet and a family letter explaining the cascade screening. In the direct arm, probands will be advised that the study staff will be contacting their family members. They will be instructed to also contact their family members prior to the study team contacting them. Approximately two weeks after this meeting with the proband, the study staff will mail letters to eligible first-degree family members of the probands. If we do not hear back from individual family members, we will follow-up with another letter, telephone call, or home visit. The information contained in the letters will be the same information for both the direct and indirect arms of the study. All interested family members will receive pre-test counseling and free, in-home, saliva-based genetic testing, and post-test counseling.
Recruiting
Has No Placebo
University of Maryland Amish Research Clinic
Have you considered Fenoglide clinical trials? We made a collection of clinical trials featuring Fenoglide, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security